SAFETY DATA SHEETS This SDS packet was issued with item: 078866723 N/A
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING Material Empirical Formula Synonyms Manufacturer Distributor Chemical Clindamycin Hydrochloride C 18 H 33 ClN 2 O 5 HCl Cleocin, Dalacin Ohm Laboratories, Inc., 1385 Livingston Ave. North Brunswick, NJ, 08907, USA. Ranbaxy Pharmaceuticals Inc., 9431, Florida Mining Blvd. East, Jacksonville, FL, 32257 2. COMPOSITION / INFORMATION ON INGREDIENTS Ingredients CAS Number Percentage Clindamycin 21462-39-5 150 /300 mg - 59.2% Non-Hazardous Ingredients 150/300 mg - 40.8% 3. HAZARDS IDENTIFICATION Fire and Explosion Health Environment Expected to be non-combustible. May cause allergic reaction. May cause eye irritation Active ingredient is not a skin irritant; Not acutely toxic (based on animal data). Adverse effects associated with the therapeutic use include gastrointestinal disturbances such as nausea, dyspepsia, and vomiting and gastrointestinal irritation. Pseudo membranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided. 4. FIRST-AID MEASURES Ingestion Inhalation Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. Remove to fresh air and keep patient at rest. Seek medical attention immediately. n/k not known Page 1 of 7
Skin Contact Eye Contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately. NOTES TO PHYSICIANS / HEALTH PROFESSIONALS Medical Treatment Medical Conditions Caused or Aggravated by Exposure Antidotes Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product. No specific antidote exists. 5. FIRE-FIGHTING MEASURES Fire and Explosion Hazards Extinguishing Media Special Firefighting Procedures Hazardous Combustion Products Not expected for the product. Use carbon dioxide, dry chemical, or water spray. During all fire fighting activities, wear appropriate protective equipment, including self contained breathing apparatus. Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen, sulfur, and chlorine. 6. ACCIDENTAL RELEASE MEASURES Personal Precautions Environmental Precautions Clean-up Methods Decontamination Procedure 7. HANDLING AND STORAGE Safe Handling and Personnel involved in clean-up should wear appropriate personal protective equipment. Minimize exposure. Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly. No specific decontamination or detoxification procedures have been identified for this product. Minimize dust generation and accumulation. If capsules are crushed and/or n/k not known Page 2 of 7
Use Storage broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment. Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames. 8. EXPOSURE CONTROLS / PERSONAL PROTECTION PERSONAL PROTECTIVE EQUIPMENT Eye Protection Respirators Other Equipment or Procedures Work / Hygienic Practices Wear safety glasses or goggles if eye contact is possible. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL. Wear appropriate clothing to avoid skin contact. Instruction of employees mandatory. Shower after work recommended. 9. PHYSICAL AND CHEMICAL PROPERTIES Physical Form (Appearance) Shape & Color (150 mg) White to off-white powder filled in Size 1 blue opaque cap/light green body hard gelatin capsules Shape & Color (300 mg) White to off-white powder filled in Size 0 turquoise blue opaque cap/ turquoise blue opaque body hard gelatin capsules 10. STABILITY AND REACTIVITY Stability Stable Conditions to Avoid n/k, as a precautionary measure, keep away from strong oxidizers. 11. TOXICOLOGICAL INFORMATION This product contains active pharmaceutical ingredient Clindamycine hydrochloride, the specific information on which is provided below. Oral Toxicity One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at dose levels up to 300 mg/kg/day (approximately 1.6 and 5.4 times the highest recommended adult human dose based on mg/m2, respectively) have shown n/k not known Page 3 of 7
clindamycin to be well tolerated. No appreciable difference in pathological findings has been observed between groups of animals treated with clindamycin and comparable control groups. Rats receiving clindamycin hydrochloride at 600 mg/kg/day (approximately 3.2 times the highest recommended adult human dose based on mg/m2) for 6 months tolerated the drug well; however, dogs dosed at this level (approximately 10.8 times the highest recommended adult human dose based on mg/m2) vomited, would not eat, and lost weight. Inhalation Toxicity Skin Effects Eye Effects Target Organ Effects n/k Pruritus, vaginitis, and rare instances of exfoliative dermatitis have been reported. May cause eye irritation Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy. Renal: Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances. Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing. Musculoskeletal: Rare instances of polyarthritis have been reported Sensitisation Genetic Toxicity Carcinogenicity Reproductive Effects May cause sensitization by skin contact Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative. Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult human dose based on mg/m2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest recommended adult human dose based on mg/m2, respectively) revealed no evidence of teratogenicity. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly n/k not known Page 4 of 7
needed. Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/ml Gastrointestinal Reactions Hypersensitivity Reactions Pharmacological Effects When Clindamycin HCl is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable. Abdominal pain, pseudo membranous colitis, esophagitis, nausea, vomiting and diarrhea. The onset of pseudo membranous colitis symptoms may occur during or after antibacterial treatment. Generalized mild to moderate morbilliform-like (maculopapular) skin rashes are the most frequently reported adverse reactions. Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, and a few cases of anaphylactoid reactions have also been reported. Serum level studies with a 150 mg oral dose of Clindamycin hydrochloride in 24 normal adult volunteers showed that clindamycin was rapidly absorbed after oral administration. An average peak serum level of 2.50 mcg/ml was reached in 45 minutes; serum levels averaged 1.51 mcg/ml at 3 hours and 0.70 mcg/ml at 6 hours. Absorption of an oral dose is virtually complete (90%), and the concomitant administration of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Serum level studies following multiple doses of Clindamycin HCl for up to 14 days show no evidence of accumulation or altered metabolism of drug. Serum half-life of clindamycin is increased slightly in patients with markedly reduced renal function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Concentrations of clindamycin in the serum increased linearly with increased dose. Serum levels exceed the MIC (minimum inhibitory concentration) for most indicated organisms for at least six hours following administration of the usually recommended doses. Clindamycin is widely distributed in body fluids and tissues (including bones). The average biological half-life is 2.4 hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites. Doses of up to 2 grams of clindamycin per day for 14 days have been well tolerated by healthy volunteers, except that the incidence of gastrointestinal side effects is greater with the higher doses. No significant levels of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges. n/k not known Page 5 of 7
Pharmacokinetic studies in elderly volunteers (61 79 years) and younger adults (18 39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours (range 3.4 5.1 h) in the elderly compared to 3.2 hours (range 2.1 4.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function. Over Dosage Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Contraindications Clindamycin HCl is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. Other Information n/k 12. ECOLOGICAL INFORMATION This material contains an active pharmaceutical ingredient that has been tested, and no environmental effects have been identified. Local regulations and procedures should be consulted prior to environmental release. Do not allow product to enter drinking water supplies, waste water or soil. 13. DISPOSAL CONSIDERATIONS Disposal Recommendations Material should be disposed of in keeping with all local and national legislation. Packaging should be disposed of in keeping with all local and national legislation. Collect for recycling or recovery if possible. The disposal method for rejected Products /returned goods must ensure that they cannot be re-sold or re-used. Regulatory Requirements Observe all local and national regulations when disposing of this product. 14. TRANSPORT INFORMATION n/k not known Page 6 of 7
The MSDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorized persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport. Transport Information Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes. 15. REGULATORY INFORMATION EU Classification and Labelling US OSHA Standard (29 CFR Part 1910.1200) OTHER US REGULATIONS 16. OTHER INFORMATION Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device. This dosage form is exempt from the requirements of the OSHA Hazard Communication Standard. Exempt The above information and recommendations are believed to be correct as on date but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose. Ranbaxy shall not be held liable for any damage resulting from handling or from contact with the above product. Ranbaxy reserves the right to revise this MSDS. n/k not known Page 7 of 7
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING Material Empirical Formula Synonyms Manufacturer Distributor Chemical Clindamycin Hydrochloride C 18 H 33 ClN 2 O 5 HCl Cleocin, Dalacin Ohm Laboratories, Inc., 1385 Livingston Ave. North Brunswick, NJ, 08907, USA. Ranbaxy Pharmaceuticals Inc., 9431, Florida Mining Blvd. East, Jacksonville, FL, 32257 2. COMPOSITION / INFORMATION ON INGREDIENTS Ingredients CAS Number Percentage Clindamycin 21462-39-5 150 /300 mg - 59.2% Non-Hazardous Ingredients 150/300 mg - 40.8% 3. HAZARDS IDENTIFICATION Fire and Explosion Health Environment Expected to be non-combustible. May cause allergic reaction. May cause eye irritation Active ingredient is not a skin irritant; Not acutely toxic (based on animal data). Adverse effects associated with the therapeutic use include gastrointestinal disturbances such as nausea, dyspepsia, and vomiting and gastrointestinal irritation. Pseudo membranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided. 4. FIRST-AID MEASURES Ingestion Inhalation Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. Remove to fresh air and keep patient at rest. Seek medical attention immediately. n/k not known Page 1 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460
Skin Contact Eye Contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately. NOTES TO PHYSICIANS / HEALTH PROFESSIONALS Medical Treatment Medical Conditions Caused or Aggravated by Exposure Antidotes Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product. No specific antidote exists. 5. FIRE-FIGHTING MEASURES Fire and Explosion Hazards Extinguishing Media Special Firefighting Procedures Hazardous Combustion Products Not expected for the product. Use carbon dioxide, dry chemical, or water spray. During all fire fighting activities, wear appropriate protective equipment, including self contained breathing apparatus. Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen, sulfur, and chlorine. 6. ACCIDENTAL RELEASE MEASURES Personal Precautions Environmental Precautions Clean-up Methods Decontamination Procedure 7. HANDLING AND STORAGE Safe Handling and Personnel involved in clean-up should wear appropriate personal protective equipment. Minimize exposure. Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly. No specific decontamination or detoxification procedures have been identified for this product. Minimize dust generation and accumulation. If capsules are crushed and/or n/k not known Page 2 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460
Use Storage broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment. Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames. 8. EXPOSURE CONTROLS / PERSONAL PROTECTION PERSONAL PROTECTIVE EQUIPMENT Eye Protection Respirators Other Equipment or Procedures Work / Hygienic Practices Wear safety glasses or goggles if eye contact is possible. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL. Wear appropriate clothing to avoid skin contact. Instruction of employees mandatory. Shower after work recommended. 9. PHYSICAL AND CHEMICAL PROPERTIES Physical Form (Appearance) Shape & Color (150 mg) White to off-white powder filled in Size 1 blue opaque cap/light green body hard gelatin capsules Shape & Color (300 mg) White to off-white powder filled in Size 0 turquoise blue opaque cap/ turquoise blue opaque body hard gelatin capsules 10. STABILITY AND REACTIVITY Stability Stable Conditions to Avoid n/k, as a precautionary measure, keep away from strong oxidizers. 11. TOXICOLOGICAL INFORMATION This product contains active pharmaceutical ingredient Clindamycine hydrochloride, the specific information on which is provided below. Oral Toxicity One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at dose levels up to 300 mg/kg/day (approximately 1.6 and 5.4 times the highest recommended adult human dose based on mg/m2, respectively) have shown n/k not known Page 3 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460
clindamycin to be well tolerated. No appreciable difference in pathological findings has been observed between groups of animals treated with clindamycin and comparable control groups. Rats receiving clindamycin hydrochloride at 600 mg/kg/day (approximately 3.2 times the highest recommended adult human dose based on mg/m2) for 6 months tolerated the drug well; however, dogs dosed at this level (approximately 10.8 times the highest recommended adult human dose based on mg/m2) vomited, would not eat, and lost weight. Inhalation Toxicity Skin Effects Eye Effects Target Organ Effects n/k Pruritus, vaginitis, and rare instances of exfoliative dermatitis have been reported. May cause eye irritation Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy. Renal: Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances. Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing. Musculoskeletal: Rare instances of polyarthritis have been reported Sensitisation Genetic Toxicity Carcinogenicity Reproductive Effects May cause sensitization by skin contact Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative. Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult human dose based on mg/m2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest recommended adult human dose based on mg/m2, respectively) revealed no evidence of teratogenicity. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly n/k not known Page 4 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460
needed. Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/ml Gastrointestinal Reactions Hypersensitivity Reactions Pharmacological Effects When Clindamycin HCl is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable. Abdominal pain, pseudo membranous colitis, esophagitis, nausea, vomiting and diarrhea. The onset of pseudo membranous colitis symptoms may occur during or after antibacterial treatment. Generalized mild to moderate morbilliform-like (maculopapular) skin rashes are the most frequently reported adverse reactions. Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, and a few cases of anaphylactoid reactions have also been reported. Serum level studies with a 150 mg oral dose of Clindamycin hydrochloride in 24 normal adult volunteers showed that clindamycin was rapidly absorbed after oral administration. An average peak serum level of 2.50 mcg/ml was reached in 45 minutes; serum levels averaged 1.51 mcg/ml at 3 hours and 0.70 mcg/ml at 6 hours. Absorption of an oral dose is virtually complete (90%), and the concomitant administration of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Serum level studies following multiple doses of Clindamycin HCl for up to 14 days show no evidence of accumulation or altered metabolism of drug. Serum half-life of clindamycin is increased slightly in patients with markedly reduced renal function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Concentrations of clindamycin in the serum increased linearly with increased dose. Serum levels exceed the MIC (minimum inhibitory concentration) for most indicated organisms for at least six hours following administration of the usually recommended doses. Clindamycin is widely distributed in body fluids and tissues (including bones). The average biological half-life is 2.4 hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites. Doses of up to 2 grams of clindamycin per day for 14 days have been well tolerated by healthy volunteers, except that the incidence of gastrointestinal side effects is greater with the higher doses. No significant levels of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges. n/k not known Page 5 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460
Pharmacokinetic studies in elderly volunteers (61 79 years) and younger adults (18 39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours (range 3.4 5.1 h) in the elderly compared to 3.2 hours (range 2.1 4.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function. Over Dosage Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Contraindications Clindamycin HCl is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. Other Information n/k 12. ECOLOGICAL INFORMATION This material contains an active pharmaceutical ingredient that has been tested, and no environmental effects have been identified. Local regulations and procedures should be consulted prior to environmental release. Do not allow product to enter drinking water supplies, waste water or soil. 13. DISPOSAL CONSIDERATIONS Disposal Recommendations Regulatory Requirements Material should be disposed of in keeping with all local and national legislation. Packaging should be disposed of in keeping with all local and national legislation. Collect for recycling or recovery if possible. The disposal method for rejected Products /returned goods must ensure that they cannot be re-sold or re-used. Observe all local and national regulations when disposing of this product. 14. TRANSPORT INFORMATION n/k not known Page 6 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460
The MSDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorized persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport. Transport Information Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes. 15. REGULATORY INFORMATION EU Classification and Labelling US OSHA Standard (29 CFR Part 1910.1200) OTHER US REGULATIONS 16. OTHER INFORMATION Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device. This dosage form is exempt from the requirements of the OSHA Hazard Communication Standard. Exempt The above information and recommendations are believed to be correct as on date but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose. Ranbaxy shall not be held liable for any damage resulting from handling or from contact with the above product. Ranbaxy reserves the right to revise this MSDS. n/k not known Page 7 of 7 Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460